RIGEL PHARMACEUTICALS INC
RIGLDrugs in Pipeline
14
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 15, 2026
22wMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
Fostamatinib disodium
Immune Thrombocytopenic Purpura
fostamatinib
Lymphoma
Fostamatinib 150 mg
IGA Nephropathy
Fostamatinib 150 mg bid
Warm Antibody Autoimmune Hemolytic Anemia
Fostamatinib disodium (R935788)
Rheumatoid Arthritis
R906289 Monosodium (R289 Na)
Low Risk Myelodysplastic Syndromes
R940343 1mg
Asthma
R348 Ophthalmic Solution, 0.2%
Keratoconjunctivitis Sicca
Olutasidenib + TMZ
High Grade Glioma
R932333
Lupus Erythematosus, Discoid
R348 Ophthalmic Solution, 0.5%
Chronic Graft-versus-host Disease
Fostamatinib Disodium / R935788
Purpura, Thrombocytopenic, Idiopathic
R926112
Rhinitis, Allergic, Seasonal
R788
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fostamatinib disodium | Phase 3 | Immune Thrombocytopenic Purpura | - | - |
fostamatinib | Phase 3 | Lymphoma | - | - |
Fostamatinib 150 mg | Phase 2 | IGA Nephropathy | - | - |
Fostamatinib 150 mg bid | Phase 2 | Warm Antibody Autoimmune Hemolytic Anemia | - | - |
Fostamatinib disodium (R935788) | Phase 2 | Rheumatoid Arthritis | - | - |
R906289 Monosodium (R289 Na) | Phase 2 | Low Risk Myelodysplastic Syndromes | - | - |
R940343 1mg | Phase 2 | Asthma | - | - |
R348 Ophthalmic Solution, 0.2% | Phase 2 | Keratoconjunctivitis Sicca | - | - |
Olutasidenib + TMZ | Phase 2 | High Grade Glioma | - | - |
R932333 | Phase 2 | Lupus Erythematosus, Discoid | - | - |
R348 Ophthalmic Solution, 0.5% | Phase 2 | Chronic Graft-versus-host Disease | - | - |
Fostamatinib Disodium / R935788 | Phase 2 | Purpura, Thrombocytopenic, Idiopathic | - | - |
R926112 | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
R788 | Phase 2 | Rheumatoid Arthritis | - | - |